학술논문
Long-Term Efficacy, Safety, and Subgroup Analysis of Savolitinib in Chinese Patients With NSCLCs Harboring METExon 14 Skipping Alterations
Document Type
Article
Author
Source
JTO Clinical and Research Reports; October 2022, Vol. 3 Issue: 10
Subject
Language
ISSN
26663643
Abstract
Savolitinib has been found to have encouraging antitumor activity and a favorable safety profile in Chinese patients with pulmonary sarcomatoid carcinoma and other NSCLCs with METexon 14 skipping alterations (METex14 positive) at the primary analysis of a phase 2 study. Here, we present the long-term efficacy and safety data of savolitinib, including subgroup analyses.